# Convalife

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/convalife

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.fukang.panyouwl.com
- Total disclosed funding: $29M
- Latest round: Series C (Mar 31, 2025)
- Investors on record: 9

## About

Based in Shanghai, China, and founded in 2015, Convalife is a pharmaceutical company focusing on cancer research and development. The company has cooperation with Fosun Pharmaceutical, Jiuzhoutong Pharmaceutical Group, and other companies. The founder and CEO, Xiaokun Shen, is a doctor of the Chinese Academy of Sciences Shanghai Institute of Materia Medica and worked at Hengrui Pharmaceuticals and Novartis Pharmaceuticals. In 2022, the CVL218 project entered clinical phase II. In March 2025, Convalife closed a series C+ funding from returning investor Vista Investment Company and new investors Panji Hongyi Venture Capital, Safe & Rich Venture Capital, Pengshui State-owned Investment.

The company is dedicated to developing drugs in the fields of tumors, viruses, and aging diseases, including PARP inhibitors CVL218 and PI3K-p110 ß/d double high selectivity inhibitor CVL237 and bispecific antibody CVL006, etc. The product pipeline covers treatment schemes for solid tumors such as breast cancer, lung cancer, bile duct cancer, and so on. The company generates revenue through developing drugs in the fields of tumors, viruses, and aging diseases, including PARP inhibitors CVL218 and PI3K-p110 ß/d double high selectivity inhibitor CVL237 and bispecific antibody CVL006, etc. The company will focus on its product commercialization layout, the global development process of multiple drug pipelines, and the company's R6D+AI new drug discovery platform.

## Funding rounds

- Series C, Mar 31, 2025 — Vista Investment Company, Safe & Rich Venture Capital, Panji Hongyi Venture Capital, Pengshui State-owned Investment
- Series C, Jan 4, 2024, $14M — Vista Investment Company
- Series A, Apr 9, 2021, $15M — Qiandao Investment Fund Management, Shangrun Investment, Shanghai Tenggang Technology
- Angel, Dec 22, 2019 — Hiway Capital, Realharmony Capital

## Investors

- Hiway Capital (https://capitalatlas.ai/funds/hiway-capital) — Angel
- Realharmony Capital (https://capitalatlas.ai/funds/realharmony-capital) — Angel
- Qiandao Investment Fund Management (https://capitalatlas.ai/funds/qiandao-investment-fund-management) — Series A
- Shangrun Investment (https://capitalatlas.ai/funds/shangrun-investment) — Series A
- Shanghai Tenggang Technology — Series A
- Vista Investment Company — Series C
- Safe & Rich Venture Capital (https://capitalatlas.ai/funds/safe-rich-venture-capital) — Series C
- Panji Hongyi Venture Capital (https://capitalatlas.ai/funds/panji-hongyi-venture-capital) — Series C
- Pengshui State-owned Investment — Series C